|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 19
|
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
|
|
Dec 19
|
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
|
|
Dec 18
|
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
|
|
Dec 11
|
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
|
|
Dec 10
|
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
|
|
Dec 10
|
Is Now the Right Time to Buy AstraZeneca Stock?
|
|
Dec 7
|
UPDATE 2-US urges makers of infant RSV shots to meet winter demand
|
|
Dec 7
|
FTC warns pharma companies on excessive drug patenting
|
|
Dec 6
|
Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas
|
|
Dec 5
|
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Dec 5
|
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
|
|
Dec 5
|
These 3 stocks are Cowen’s best ideas for 2024 including AstraZeneca and Datadog
|
|
Dec 4
|
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
|
|
Dec 3
|
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
|
|
Dec 3
|
UPDATE 1-AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
|
|
Dec 3
|
AstraZeneca ties up with AI biologics company to develop cancer drug
|
|
Dec 1
|
Directors’ Deals: Strategy refresh spurs Unilever directors
|
|
Dec 1
|
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
|
|
Nov 30
|
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
|